CA2898644A1 - Composition for ophthalmic administration - Google Patents

Composition for ophthalmic administration Download PDF

Info

Publication number
CA2898644A1
CA2898644A1 CA2898644A CA2898644A CA2898644A1 CA 2898644 A1 CA2898644 A1 CA 2898644A1 CA 2898644 A CA2898644 A CA 2898644A CA 2898644 A CA2898644 A CA 2898644A CA 2898644 A1 CA2898644 A1 CA 2898644A1
Authority
CA
Canada
Prior art keywords
composition
compound
buffer
eye
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2898644A
Other languages
English (en)
French (fr)
Inventor
Hong Ren
Thomas Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CA2898644A1 publication Critical patent/CA2898644A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2898644A 2013-01-24 2014-01-24 Composition for ophthalmic administration Abandoned CA2898644A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756306P 2013-01-24 2013-01-24
US61/756,306 2013-01-24
PCT/US2014/013036 WO2014117010A2 (en) 2013-01-24 2014-01-24 Composition for ophthalmic administration

Publications (1)

Publication Number Publication Date
CA2898644A1 true CA2898644A1 (en) 2014-07-31

Family

ID=50102221

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2898644A Abandoned CA2898644A1 (en) 2013-01-24 2014-01-24 Composition for ophthalmic administration

Country Status (5)

Country Link
US (1) US20140206708A1 (https=)
EP (1) EP2948130B1 (https=)
JP (1) JP6351629B2 (https=)
CA (1) CA2898644A1 (https=)
WO (1) WO2014117010A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CN114469991A (zh) 2016-04-14 2022-05-13 阿祖拉眼科有限公司 用于治疗睑板腺功能障碍的二硫化硒组合物
CN107805212B (zh) * 2017-11-03 2021-08-20 宿迁德威化工股份有限公司 一种2-甲基-5-氨基苯磺酰胺的制备方法
CA3166357A1 (en) 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions for composition and sensitivity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1227128A (en) * 1916-11-06 1917-05-22 Ohio Blower Company Conveying mechanism.
ZA815175B (en) * 1980-08-01 1982-09-29 Smith & Nephew Ass Pharmaceutical composition
HU207222B (en) * 1990-02-15 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing eyedrops containing primycin
CN1230882A (zh) * 1996-09-20 1999-10-06 博士伦公司 再湿润隐形眼镜和减轻眼部干燥的方法和组合物
ES2396598T3 (es) * 2000-08-25 2013-02-22 Senju Pharmaceutical Co., Ltd. Preparaciones en forma de suspensiones acuosas
WO2002085248A2 (en) * 2001-04-23 2002-10-31 Board Of Regents The University Of Texas System Prostanoids augment ocular drug penetration
KR20090053892A (ko) * 2006-07-25 2009-05-28 오스모티카 코프. 점안액
EP2303184A4 (en) * 2008-06-24 2013-06-19 Quadra Logic Tech Inc COMBINATION TREATMENT OF GREEN STAR
JP6100997B2 (ja) * 2008-11-04 2017-03-22 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 酸化感受性ポリマーのための包装材としてのコンポジットフィルムの使用、酸化感受性ポリマーの包装方法、及び該コンポジットフィルムを含有する包装体
CN102470135A (zh) * 2009-07-28 2012-05-23 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20120022149A1 (en) * 2010-07-21 2012-01-26 Chowhan Masood A Pharmaceutical composition with enhanced solubility characteristics

Also Published As

Publication number Publication date
JP6351629B2 (ja) 2018-07-04
JP2016506931A (ja) 2016-03-07
WO2014117010A2 (en) 2014-07-31
EP2948130A2 (en) 2015-12-02
EP2948130B1 (en) 2019-03-13
US20140206708A1 (en) 2014-07-24
WO2014117010A3 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CA2768543C (en) Compositions and methods for inhibition of the jak pathway
EP2788028B1 (en) Topical formulation for administering a compound
JP2018115205A (ja) 白斑の治療法
ES2686532T3 (es) 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide
EP2948130B1 (en) Composition for ophthalmic administration
JP2019534269A (ja) Ｃｓｆ−１ｒの阻害剤を使用して眼疾患を治療するための方法
CN107106566A (zh) 晶状体硬化抑制剂
JPWO2018199224A1 (ja) 抗アレルギー剤
HK1193746A (en) 2,4 substituted pyrimidinediamines for use in discoid lupus
HK1193746B (en) 2,4 substituted pyrimidinediamines for use in discoid lupus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190114

FZDE Discontinued

Effective date: 20210831